NBIX GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Neurocrine Biosciences Inc
Exchange: NASDAQSector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Biosciences, Inc. Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, endocrine, psychiatric and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids,* as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science.
Did you know?
Earnings per share grew at a 50.0% CAGR.
Current Price
$131.78
+0.08%GoodMoat Value
$213.39
61.9% undervaluedProfile
Valuation (TTM)
Market Cap$13.14B
P/E27.45
EV—
P/B4.04
Shares Out99.71M
P/Sales4.59
Revenue$2.86B
EV/EBITDA15.84
Neurocrine Biosciences Inc (NBIX) Quality Analysis
NBIX Profitability
Profitability trend analysis coming soon
NBIX Growth
Growth trend analysis coming soon
NBIX Financial Health
Financial health indicators coming soon
NBIX Quality & Fundamental Analysis
Neurocrine Biosciences Inc (NBIX) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ. This quality analysis page evaluates Neurocrine Biosciences Inc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Neurocrine Biosciences Inc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 16.73% and a return on equity (ROE) of 14.71%. Return on assets (ROA) stands at 10.33%.
The debt-to-equity ratio is 0.13, with a current ratio of 3.39. Operating margin is 21.64%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Neurocrine Biosciences Inc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.